Résumés
Résumé
Le préconditionnement ischémique est un concept né il y a une quinzaine d’années. Dans cet article, nous présentons les généralités sur la protection anti-ischémique qui en découle ainsi que la part du mécanisme qui a pu être éclaircie à ce jour. Nous discutons l’application clinique de ce phénomène et envisageons comment l’évolution récente du concept ainsi que les derniers travaux laissent entrevoir d’importants développements dans un avenir proche.
Summary
Ischemic preconditioning affords the most powerful protection to a heart submitted to a prolonged ischemia-reperfusion. During the past decade, a huge amount of work allowed to better understand the features of this protective effect as well as the molecular mechanisms. Ischemic preconditioning reduces infarct size and improves functional recovery ; its effects on arrhythmias remain debated. Triggering of the protection involves cell surface receptors that activate pro-survival pathways including protein kinase C, PI3-kinase, possibly Akt and ERK1/2, whose downstream targets remain to be determined. Much attention has been recently focused on the role of mitochondrial K+ATP channels and the permeability transition pore that seem to play a major role in the progression toward irreversible cellular injury. Based on these experimental studies attempts have been made to transfer preconditioning from bench to bedside. Human experimental models of ischemic preconditioning have been set up, including cardiac surgery, coronary angioplasty or treadmill exercise, to perform pathophysiological studies. Yet, protecting the heart of CAD (coronary artery disease) patients requires a pharmacological approach. The IONA trial has been an example of the clinical utility of preconditioning. It helped to demonstrate that chronic administration of nicorandil, a K+ATP opener that mimicks ischemic preconditioning in experimental preparations, improves the cardiovascular prognosis in CAD patients. Recent experimental studies appear further encouraging. It appears that “postconditioning” the heart (i.e. performing brief episodes of ischemia-reperfusion at the time of reperfusion) is as protective as preconditioning. In other words, a therapeutic intervention performed as late as at the time of reflow can still significantly limit infarct size. Further work is needed to determine whether this may be transfered to the clinical practice.
Parties annexes
Références
- 1. Murry CE, Jennings RB, Reimer KA. « Preconditioning » with ischemia : a delay of lethal cell injury in ischemic myocardium. Circulation 1986 ; 5 : 1124-36.
- 2. Piot CA, Padmanaban DD, Ursell PC, et al. Ischemic preconditioning decreases apoptosis in rat heart in vivo. Circulation 1997 ; 96 : 1598-604.
- 3. Argaud L, Prigent AF, Chalabreysse L, et al. Ceramide in the antiapoptotic effect of ischemic preconditioning. Am J Physiol Heart Circ Physiol 2004 ; 286 : H246-51.
- 4. Ovize M, Kloner RA, Przyklenk K. Preconditioning and contractile function. In : Przyklenk K, Yellon N, eds. Preconditioning : the concept of endogenous protection. Dordrecht : Kluwer Publisher, 1994.
- 5. Ovize M, Przyklenk K, Kloner RA. « Preconditioning » does not attenuate myocardial « stunning ». Circulation 1992 ; 85 : 2247-54.
- 6. Ovize M, Aupetit JF, Rioufol G, et al. Preconditioning reduces infarct size but accelerates time to ventricular fibrillation in the pig heart. Am J Physiol 1995 ; 269 : H72-79.
- 7. Shiki K, Hearse DJ. « Preconditioning » of ischemic myocardium :reperfusion-induced arrhythmias. Am J Physiol 1987 ; 253 : H1470-76.
- 8. Ovize M, Przyklenk K, Kloner RA. Stretch preconditions the canine myocardium. Am J Physiol 1994 ; 266 : H137-46.
- 9. Schultz JEL, Rose E, Yao Z, Gross GJ. Evidence for involvment of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995 ; 268 : H2157-61.
- 10. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991 ; 84 : 350-6.
- 11. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993 ; 72 : 1293-9.
- 12. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994 ; 266 : H1145-52.
- 13. Yellon DM, Downey JM. Preconditioning the myocardium : from cellular physiology to clinical cardiology. Physiol rev 2003 ; 83 : 1113-51.
- 14. Garlid KD, Paucek P, Yarov-Yarovoy V. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res 1997 ; 81 : 1072-82.
- 15. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992 ; 70 : 223-33.
- 16. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature 1991 ; 352 : 244-7.
- 17. O’Rourke B. Mitochondrial K+ATP channels in preconditioning. Circ Res 2000 ; 87 : 845-55.
- 18. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in necrosis and apoptosis. Annu Rev Physiol 1998 ; 60 : 619-42.
- 19. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochem Biophys Acta 1995 ; 1241 : 139-76.
- 20. Duchen MR, McGuinness O, Brown LA, Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 1993 ; 27 : 1790-4.
- 21. Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993 ; 25 : 1461-9.
- 22. Argaud L, Gateau-Roesch O, Chalabreysse L, et al. Preconditioning delays Ca2+-induced mitochondrial permeability transition. Cardiovasc Res 2004 ; 61 : 115-22.
- 23. Javadov SA, Clarke S, Das M, et al. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003 ; 549 : 513-24.
- 24. Piriou V, Chiari P, Gateau-Roesch O, et al. Desflurane-induced preconditioning delays mitochondrial permeability transition pore opening. Anesthesiology 2004 ; 100 : 581-8.
- 25. Wang L, Cherednichenko G, Hernandez L, et al. Preconditioning limits mitochondrial Ca2+ during ischemia in rat hearts : role of K+ATP channels. Am J Physiol 2001 ; 280 : H2321-8.
- 26. Leesar MA, Stoddard MF, Ahmed M, et al. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997 ; 95 : 2500-7.
- 27. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994 ; 90 : 700-5.
- 28. IONA Study group. Effect of nicorandil on coronary events in patients with stable angina : the impact of nicorandil in angina (IONA) randomised trial. Lancet 2002 ; 359 : 1269-75.
- 29. Zhao ZQ, Corvera JS, Hlakos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion : comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003 ; 285 : H579-88.
- 30. Derek J, Hausenloy H, Derek M. New directions for protecting the heart against ischaemia-reperfusion injury : targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004 ; 61 : 448-60.
- 31. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischemia but open upon reperfusion. Biochem J 1995 ; 307 : 93-8.
- 32. Argaud L, Gateau-Roesch O, Loufouat J, Ovize M. Cyclosporin delays calcium-induced permeability transition when administered at reperfusion. Eur Heart J 2003 ; 2530 (abstract).